LAUSR

Recombinant adeno‐associated viral (AAV)‐mediated therapeutic gene transfer to dorsal root ganglia (DRG) is an effective and safe tool for treating chronic pain. However, AAV with various constitutively active promoters leads to transgene expression predominantly to neurons, while glial cells are refractory to AAV transduction in the peripheral nervous system. The present study evaluated whether in vivo satellite glial cell (SGC) transduction in the DRG can be enhanced by the SGC‐specific GFAP promoter and by using shH10 and shH19, which are engineered capsid variants with Müller glia‐prone transduction. Titer‐matched AAV6 (as control), AAVshH10, and AAVshH19, all encoding the EGFP driven by the constitutively active CMV promoter, as well as AAV6‐EGFP and AAVshH10‐EGFP driven by a GFAP promoter (AAV6‐GFAP‐EGFP and AAVshH10‐GFAP‐EGFP), were injected into DRG of adult male rats. Neurotropism of gene expression was determined and compared by immunohistochemistry. Results showed that injection of AAV6‐ and AAVshH10‐GFAP‐EGFP induces robust EGFP expression selectively in SGCs, whereas injection of either AAVshH10‐CMV‐EGFP or AAVshH19‐CMV‐EGFP into DRG resulted in a similar in vivo transduction profile to AAV6‐CMV‐EGFP, all showing efficient transduction of sensory neurons without significant transduction of glial cell populations. Coinjection of AAV6‐CMV‐mCherry and AAV6‐GFAP‐EGFP induces transgene expression in neurons and SGCs separately. This report, together with our prior studies, demonstrates that the GFAP promoter rather than capsid tropism determines selective gene expression in SGCs following intraganglionic AAV delivery in adult rats. A dual AAV system, one with GFAP promoter and the other with CMV promoter, can efficiently express transgenes selectively in neurons versus SGCs.